


WHO Good Reliance Practices and support to ASEAN joint assessment procedures

Asia Partnership Conference of Pharmaceutical Associations Conference

Tokyo, Tuesday 23rd April 2024



Marie Valentin
Team Lead, Facilitated Product Introduction
WHO Regulation and Prequalification Department



Reliance at the core of a more efficient use of global resources

>70% of countries have weak national regulatory systems

Need to facilitate access to quality-assured medical products and to build capacity

Reliance to promote better use of limited resources and to strengthen global regulatory oversight

Apply a risk-based approach, avoid duplication where possible, full range of reliance options (work sharing, abridged pathways, etc.)

Implementation

Voluntary participation, change mindset, start small, learning by doing, harmonization facilitator but not pre-requisite

WHO Listed Authorities
Transparent, evidence-based system to define trusted authorities

Source of information on reliance


WHO Good Reliance Practices

Annex 10

Good reliance practices in the regulation of medical products: high level principles and considerations

Background

WHO supports reliance on the work of other regulators as a general principle in order to make the best use of available resources and expertise. This principle allows leveraging the output of others whenever possible while placing a greater focus at national level on value-added regulatory activities that cannot be undertaken by other authorities, such as, but not limited to: vigilance, market surveillance, and oversight of local manufacturing and distribution. Reliance



Adopted by WHO Expert Committee on Specification for Pharmaceutical Products in October 2020, published in March 2021 <https://www.who.int/publications/i/item/55th-report-of-the-who-expert-committee-on-specifications-for-pharmaceutical-preparations>

Short eLearning Module of main principles and examples of reliance (Oct 2022)
<https://openwho.org/courses/good-reliance-practices>

International Pharmaceutical Regulators Programme
Questions & Answers on Reliance
https://admin.iprp.global/sites/default/files/2022-11/IPRP_RelianceQ%26As_2022_0930.pdf



IPRP Questions and Answers document¹ on Reliance
Version dated 30 September 2022

Table of Contents

1. What is reliance ?	2
2. What is "not" reliance ?	2
3. Why is reliance important for the regulatory oversight of medical products?	3
4. Do National Regulatory Authorities maintain their independence and sovereignty when using reliance?	3
5. What are the main principles of reliance?	4
6. What competences are required in applying reliance?	4
8. What type of reliance models exist?	5
10. How can an NRA start using reliance models?	6
11. What is the risk-based approach in reliance?	6
12. At which stages of the product life cycle can reliance be used?	7

WHO Support to ASEAN Joint Assessment Coordinating Group

Support and facilitation of Pharmaceutical Product Working Group (PPWG) since inception, 2000

Establishment of a Joint Assessment Coordination Group (JAGG) in 2017 (PPWG + WHO)

Development/maintenance of **ASEAN JA procedures** (procedural documents, FAQ, list of priority products)

Coordination facilitation of **ASEAN joint assessment**


Development of a dedicated **IT platform** (Joint Assessment Information Management System JAIMS)

Advocacy to NRA and companies

Coordination of **exchange of administrative tools and agreements**

ASEAN Joint Assessment concept and principles

Same application



- Open to all 10 ASEAN NRAs on a **voluntary basis**
- **Minimum of 3 NRAs**
- Administrative/local submission/assessment is conducted by individual NRAs in parallel/before the technical assessment starts
- **Final regulatory decision taken by each NRA** (according to national timelines) based on joint assessment report and national-relevant considerations if applicable (30 to 90 days)



* Can be used by other ASEAN non-participating NRAs


ASEAN Joint Assessment - Achievements

Five completed joint assessments

Product	Therapeutic area	NRAs	Technical support	Timelines	Year (JA)
Pyronaridine-artesunate	Malaria	10 NRAs Lead Malaysia	WHO & EMA (Art. 58)	Longer as pilot	2019
Tafenoquine succinate	Malaria	4 NRAs: Myanmar, Philippines, Vietnam, Thailand	WHO & TGA	< 5 months	2021
Two cabotegravir formulations (tablets and injectable)	HIV	5 NRAs: Malaysia, Myanmar, Philippines , Vietnam, Thailand	WHO & TGA	~ 6 months	2023
Ocrelizumab (first biological product)	Multiple sclerosis	6 NRAs: Thailand, Indonesia, Lao PDR, Cambodia, Indonesia and The Philippines	WHO & TGA	< 6 months	2023


- Technical support of Australia TGA (unredacted assessment reports, TGA experts)
- JA reports can be used by other ASEAN NRAs that did not participate but may receive same application
- ASEAN successfully revised in 2022. Second revision starting in 2024.
- ASEAN JA information management system (JAIMS) developed to support applications process and provide a centralized platform for ASEAN joint assessment procedures.

ASEAN Joint Assessment – Application process



Reference NRAs are drawn from those defined by WHO as 'stringent' NRAs (SRAs): <https://www.who.int/initiatives/who-listed-authority-reg-authorities/SRAs>
Occasionally, ASEAN NRAs may decide to rely on a different NRA if this is needed and justified.

ASEAN Joint Assessment – Timelines



Duration of national Decision-making Process: Number of working days:

Brunei Darussalam 60 – Cambodia 90 – Indonesia 45 - Lao PDR 45 – Malaysia 30 – Myanmar 90 (standard)/60 (urgent) – Philippines 30 – Singapore 30 – Thailand 30 – Viet Nam 60

ASEAN Joint Assessment – Published information

ASEAN's Joint Assessments Coordinating Group periodically publishes a list of priority product categories eligible for the Joint Assessment Procedure, as referred in the document "Information for Applicants" available on this website.

No	Pharmaceutical and Biological Products (as applicable)
1	Products for the treatment of hepatitis B
2	Products for the treatment of hepatitis C
3	Products for the treatment of cancer ¹
4	Products for the treatment of HIV/AIDS
5	Products for the treatment of TB
6	Products for the treatment of Malaria
7	Products for the treatment of treatment-resistant depression
8	Products for the treatment of interstitial lung disease
9	Products for the treatment of chronic kidney disease
10	Products for the treatment of autoimmune diseases such as Crohn's disease, rheumatoid arthritis, psoriatic arthritis, generalized pustular psoriasis
11	Products for the treatment of Alzheimer's disease
12	Products containing new anti-infective substances
13	Products for Maternal and Reproductive Health
14	Products for the treatment of rare diseases (orphan drugs)
15	Vaccines



Standard and Conformance

POLICY & GUIDELINES

<https://asean.org/our-communities/economic-community/standard-and-conformance/key-documents-publications/>

8. Pharmaceutical Product Working Group (PPWG)

- ASEAN Pharmaceutical Regulatory Policy
- Guidelines for Implementation of Harmonised Accreditation in ASEAN
- Glossary for ACTD & ACTR
- ASEAN Common Technical Documents (ACTD)
- ASEAN Common Technical Dossier (ACTD) Revision 1
 - Part I Organisation of Dossier
 - Part II Quality
 - Part III Nonclinical Document
 - Part IV Clinical Document
- ASEAN Common Technical Requirements (ACTR)
 - ACTR Quality
 - ACTR Safety and Efficacy
 - ASEAN Guidelines for Validation of Analytical Procedure for Vaccine
 - ASEAN Guideline on Stability Study of Drug Product Revision 2
- Labelling
- ASEAN Variation Guideline for Pharmaceutical Product Revision 1
- ASEAN Variation Guideline for Pharmaceutical Product Revision 2
- Question and Answer (Q&A)
 - Q&A on ASEAN Stability Guideline
 - Q&A for Stability Guideline on Vaccine
- Joint Assessment Coordinating Group (JACG)
 - List of Priority Product Types/Categories for ASEAN Joint Assessment Procedure
 - Frequently Asked Questions (FAQ) on the ASEAN Joint Assessment (JA) Procedure
 - ASEAN Joint Assessment Procedure for Pharmaceutical Products Information for applicants
 - Joint Assessments Information Management System (JAIMS) demo link: <https://youtu.be/IAwtK2iV-UQ>
 - Open Q & A Session between Industry Association Representatives with WHO on Joint Assessment Activities
- Joint Sectoral Committee on ASEAN MRA for Bioequivalence Study Report (JSC MRA BE)
 - Technical Documents for Implementation ASEAN MRA for Bioequivalence Study Report
 - Procedures and Manual of Joint Sectoral Committee (JSC) and Annexes
 - Operation Manual of the Panel of Experts (PoE) and Annexes
 - Manual for Application of Bioequivalence (BE) Centre to be listed under ASEAN MRA BE and Annexes

Chair: NPRA, Malaysia
Co-Chair: FDA, Thailand

1. List of priority product categories eligible for joint assessment:

https://www.npra.gov.my/media/attachments/2022/04/11/proposed-list-of-priority-products_22mar2022.pdf

2. Detailed information about the procedure and submitting an application:

<https://www.npra.gov.my/media/attachments/2022/04/20/information-for-the-applicants.pdf>

3. Questions and Answers document on the JA procedure:

<https://www.npra.gov.my/media/attachments/2022/04/20/frequently-asked-questions.pdf>

4. JAIMS demo link:

<https://youtu.be/IAwtK2iV-UQ>

ASEAN Joint Assessment - Key messages going forward



1. Overwhelming for NRAs at all maturity levels to fulfil all regulatory work alone and independently from other regulators;
2. **Many reliance tools available to NRAs and Industry** to facilitate the regulatory decisions, such as ASEAN JA and WHO Collaborative Registration Procedure;
3. One JA is starting and **healthy pipeline for future JA**;
4. **Best use of global regulatory resources and time.**

Acknowledgement

Joint Assessment of Marketing Authorization Applications: *Cooperation Among ASEAN Drug Regulatory Authorities*

Rosilawati Ahmad

National Pharmaceutical
Regulatory Agency, Malaysia

Tharnkamol Chanprapaph

Food and Drug Administration,
Thailand

Samvel Azatyan

World Health Organization

Azuana Ramli

National Pharmaceutical Regulatory
Agency, Malaysia

Mariana Roldao Santos


World Health Organization

Valerio Reggi

World Health Organization

Prapassorn Thanaphollert

World Health Organization



Equitable access to affordable quality medicines and other health products requires **an integrated approach** with all stakeholders



**WORKING
TOGETHER**

Marie Valentin – valentinm@who.int, prequalreg@who.int
Team Lead, Facilitated Product Introduction
WHO Regulation and Prequalification Department